129 related articles for article (PubMed ID: 38884296)
21. Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.
Zhang J; Wang Y; Wang J; Hu J; Chen S; Jin J; Liu T; Zhou J; Hu Y; Ma D; Huang X; Ji C; Hou M
Blood Cancer J; 2018 Jun; 8(7):61. PubMed ID: 29915172
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Imatinib in Paediatric CML - A Single Centre Study.
Smeding C; Szydło A; Pieluszczak K; Grzeszkiewicz K; Pawelec K
In Vivo; 2019; 33(3):869-875. PubMed ID: 31028210
[TBL] [Abstract][Full Text] [Related]
23. Blepharospasm and periorbital edema after imatinib mesylate: improvement with botulinum toxin.
Teive HAG; Germiniani FMB; Munhoz RP; Camargo CHF
Arq Neuropsiquiatr; 2020 Jan; 78(1):58-59. PubMed ID: 32074181
[No Abstract] [Full Text] [Related]
24. Skin and oral lesions associated to imatinib mesylate therapy.
Basso FG; Boer CC; Corrêa ME; Torrezan M; Cintra ML; de Magalhães MH; da Silva Santos P; de Souza CA
Support Care Cancer; 2009 Apr; 17(4):465-8. PubMed ID: 19037666
[TBL] [Abstract][Full Text] [Related]
25. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
26. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
Vatel O; Aumont C; Mathy V; Petit M; Feriel J; Sloma I; Bennaceur-Griscelli A; Turhan AG
Leuk Lymphoma; 2017 Feb; 58(2):473-474. PubMed ID: 27389710
[No Abstract] [Full Text] [Related]
27. Generic Imatinib in Chronic Myeloid Leukemia Treatment: Long-Term Follow-up.
Ćojbašić I; Mačukanović-Golubović L; Vučić M; Ćojbašić Ž
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e526-e531. PubMed ID: 31239209
[TBL] [Abstract][Full Text] [Related]
28. Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
Singh S; Sharma PK
Indian J Pharmacol; 2016; 48(4):458-459. PubMed ID: 27756963
[TBL] [Abstract][Full Text] [Related]
29. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Zonder JA; Schiffer CA
Curr Hematol Malig Rep; 2006 Sep; 1(3):141-51. PubMed ID: 20425345
[TBL] [Abstract][Full Text] [Related]
30. Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
Shi CR; Nambudiri VE
Am J Hematol; 2018 Mar; 93(3):467-468. PubMed ID: 28836284
[No Abstract] [Full Text] [Related]
31. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
32. Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.
Osorio S; Escudero-Vilaplana V; Gómez-Centurión I; González-Arias E; García-González X; Díez JL
J Oncol Pharm Pract; 2019 Apr; 25(3):694-698. PubMed ID: 29199506
[TBL] [Abstract][Full Text] [Related]
33. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
Markovic U; Bulla A; Leotta S; Stella S; Consoli ML; TambÈ L; Conticello C; DI Raimondo F; Stagno F
Anticancer Res; 2020 Sep; 40(9):5313-5317. PubMed ID: 32878823
[TBL] [Abstract][Full Text] [Related]
34. The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial.
Austin GM; Knight K; Bell J; Carter A; Heartin E; Watson D; Foroni L; Christmas SE; Polydoros F; Clark RE
Br J Haematol; 2019 May; 185(4):791-793. PubMed ID: 30408160
[No Abstract] [Full Text] [Related]
35. Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study.
Korkmaz S; Dal MS; Berber I; Sahin DG; Dogu MH; Ayyildiz O; Nizam I; Albayrak M; Esen R; Namdaroglu S; Sencan M; Akay OM; Hacioglu S; Yildirim R; Eser A; Tombak A; Pala C; Ilhan O
Geriatr Gerontol Int; 2015 Jun; 15(6):729-35. PubMed ID: 25257190
[TBL] [Abstract][Full Text] [Related]
36. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
Suttorp M; Schulze P; Glauche I; Göhring G; von Neuhoff N; Metzler M; Sedlacek P; de Bont ESJM; Balduzzi A; Lausen B; Aleinikova O; Sufliarska S; Henze G; Strauss G; Eggert A; Kremens B; Groll AH; Berthold F; Klein C; Groß-Wieltsch U; Sykora KW; Borkhardt A; Kulozik AE; Schrappe M; Nowasz C; Krumbholz M; Tauer JT; Claviez A; Harbott J; Kreipe HH; Schlegelberger B; Thiede C
Leukemia; 2018 Jul; 32(7):1657-1669. PubMed ID: 29925908
[TBL] [Abstract][Full Text] [Related]
37. Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy.
Ćojbašić I; Mačukanović-Golubović L; Vučić M; Tijanić I
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):696-702. PubMed ID: 28712742
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.
Miura M
Biol Pharm Bull; 2015; 38(5):645-54. PubMed ID: 25947908
[TBL] [Abstract][Full Text] [Related]
39. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
[TBL] [Abstract][Full Text] [Related]
40. Acute pancreatitis in a patient treated with imatinib and gefitinib.
Escudero-Vilaplana V; Collado-Borrell R; Villanueva-Bueno C; Álvarez R; Herranz A; Sanjurjo M
J Oncol Pharm Pract; 2021 Jun; 27(4):980-983. PubMed ID: 32799779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]